Paradigm Clinical Research

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis2 trials
• Type 2 diabetes2 trials
• Melanoma1 trial
• Obesity1 trial
• Type 1 diabetes1 trial

Phase

• Phase 33 trials
• Phase 22 trials
• Phase 11 trial

Status

• Recruiting2 trials
• Active, not recruiting1 trial
• Completed1 trial
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Novo Nordisk A/S3 trials
• Phio Pharmaceuticals Inc.1 trial
• United Therapeutics1 trial
• Vicore Pharma AB1 trial

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

  NCT07797335· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Vicore Pharma AB· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· United Therapeutics· Source

  Contact: Chery Bolovits

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Idiopathic pulmonary fibrosis1 recruiting
• Obesity1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Withdrawn

  A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

  NCT07357740· Phase 2· Novo Nordisk A/S· Source

• Completed

  Intratumoral PH-762 for Cutaneous Carcinoma

  NCT06014086· Phase 1· Phio Pharmaceuticals Inc.· Source